Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

NCT02899299 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

605

Enrollment

INDUSTRY

Sponsor class

Conditions

Mesothelioma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]